

**British American Tobacco p.l.c. (“BAT”) Annual General Meeting 2021:  
Responses to questions submitted by shareholders after the publication of  
the Shareholder Engagement Video before the Meeting via the ‘AGM  
Questions’ form on bat.com**

*We would like to thank our shareholders for taking the time to submit questions on these important issues. In the spirit of brevity and clarity, we have edited the questions and responded as completely and concisely as possible.*

*The Chairman responded to shareholder questions received prior to the recording of the Shareholder Engagement Video, a transcript of the responses to these questions is available here:*

*[https://www.bat.com/group/sites/uk\\_9d9kcy.nsf/vwPagesWebLive/DO57YMK7/\\$FILE/medMDC2AFEE.pdf?openelement](https://www.bat.com/group/sites/uk_9d9kcy.nsf/vwPagesWebLive/DO57YMK7/$FILE/medMDC2AFEE.pdf?openelement)*

---

**SUMMARISED QUESTION:**

Would BAT consider investing in a non-tobacco business, such as an alcohol or soft drinks manufacturing business if it improved capital returns?

**OUR RESPONSE:**

*We are committed to transforming BAT.*

*In 2020, we defined our Corporate Purpose to build A Better Tomorrow™.*

*We have a clear vision to transform into a high growth, multi-category consumer goods business, with a purpose to reduce its health impact.*

*Our multi-category strategy is driven by evolving consumer needs. At our investor day in March last year, we set out expansion beyond nicotine as a possible next step. We are exploring this space at the moment.*

*As previously communicated, we have launched a Vapour CBD trial in Manchester in the UK and also a R&D collaboration with Organigram, a leading Canadian cannabis licensed producer..*

---

## **About this Document and Forward-Looking Statements**

This is a document produced by British American Tobacco p.l.c. Associate companies are excluded. References to 'British American Tobacco', 'BAT', 'we', 'us' and 'our' when denoting opinion refer to British American Tobacco p.l.c. (the Company, and together with its subsidiaries, the "Group"), and when denoting tobacco business activity refer to Group operating companies, collectively or individually as the case may be. This document contains certain forward-looking statements, made within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, regarding our intentions, beliefs or current expectations reflecting knowledge and information available at the time of preparation and concerning, amongst other things, the future payment of dividends and sustainability practices. BAT undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

These statements are often, but not always, made through the use of words or phrases such as "believe," "anticipate," "could," "may," "would," "should," "intend," "plan," "potential," "predict," "will," "estimate," "strategy" and similar expressions. It is believed that the expectations reflected in this document are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated, including: the impact of competition from illicit trade; the impact of adverse domestic or international legislation and regulation; the inability to develop, commercialise and deliver the Group's New Categories strategy; the impact of market size reduction and consumer down-trading; adverse litigation and dispute outcomes and the effect of such outcomes on the Group's financial condition; the impact of significant increases or structural changes in tobacco, nicotine and New Categories related taxes; translational and transactional foreign exchange rate exposure; changes or differences in domestic or international economic or political conditions; the ability to maintain credit ratings and to fund the business under the current capital structure; the impact of serious injury, illness or death in the workplace; adverse decisions by domestic or international regulatory bodies; and changes in the market position, businesses, financial condition, results of operations or prospects of the Group.

The material in this document is provided for the purpose of giving information about the Company to stakeholders only and is not intended for general consumers. The Company, its directors, employees, agents or advisers do not accept or assume responsibility to any other person to whom this material is shown or into whose hands it may come and any such responsibility or liability is expressly disclaimed. The material in this document is not provided for product advertising, promotional or marketing purposes. This material does not constitute and should not be construed as constituting an offer to sell, or a



solicitation of an offer to buy, any of our products. Our products are sold only in compliance with the laws of the particular jurisdictions in which they are sold.

Additional information concerning these and other factors can be found in BAT's filings with the U.S. Securities and Exchange Commission ("SEC"), including the Annual Report on Form 20-F and Current Reports on Form 6-K, which may be obtained free of charge at the SEC's website, <http://www.sec.gov>, and BAT's Annual Reports, which may be obtained free of charge from the British American Tobacco website [www.bat.com](http://www.bat.com).

British American Tobacco p.l.c.  
Globe House  
4 Temple Place  
London  
WC2R 2PG

Company number 3407696

28 April 2021